Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Saved in:

Bibliographic Details
Main Authors:	Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Blood Neoplasia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950328025000172
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
by: Stine Ulrik Mikkelsen, et al.
Published: (2018-08-01)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
by: O. G. Golovina, et al.
Published: (2024-11-01)

Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01)

Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib
by: Liesl A. Butler, et al.
Published: (2025-04-01)

PREDICTORS OF RESPONSE TO RUXOLITINIB THERAPY IN PATIENTS WITH MYELOFIBROSIS
by: Irina Turtanova, et al.
Published: (2025-07-01)

Myelofibrosis: Treatment Options After Ruxolitinib Failure
by: Ruth Stuckey, et al.
Published: (2025-06-01)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
by: Sunny Sandhu, et al.
Published: (2022-01-01)

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
by: David M. Ross, et al.
Published: (2025-08-01)

Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis
by: Mehmet S Pepeler, et al.
Published: (2018-10-01)

Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01)

Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis
by: Sara Villar, et al.
Published: (2025-04-01)

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review
by: Xiaohong Liu, et al.
Published: (2025-08-01)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
by: María Teresa Gómez-Casares, et al.
Published: (2017-11-01)

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
by: Joshua W. Bliss, et al.
Published: (2024-12-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

Case report: Successful use of ruxolitinib to treat interstitial pneumonia as an unusual primary presentation in primary myelofibrosis—two birds with one stone
by: Pingping Xiao, et al.
Published: (2024-11-01)

Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib
by: Alessandro Laganà, et al.
Published: (2025-01-01)

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01)

Myelofibrosis-Related Arthritis Successfully Treated with Hydroxyurea
by: Xavier Guillot, et al.
Published: (2014-01-01)

Treatment Strategies Used in Treating Myelofibrosis: State of the Art
by: Massimo Martino, et al.
Published: (2024-10-01)

TREATMENT OF BLAST PHASE MYELOPROLIFERATIVE NEOPLASM WITH THE COMBINATION OF AZACITIDINE, VENETOCLAX AND RUXOLITINIB
by: Fidan Khalilova, et al.
Published: (2025-07-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Targeted Therapy of Myelofibrosis
by: OYu Vinogradova, et al.
Published: (2017-10-01)

Repigmentation of vitiligo with 5-fluorouracil tattooing in combination with topical ruxolitinib: A case report
by: Betul Macit, MD, et al.
Published: (2025-04-01)

Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease
by: Neslihan Mandaci Sanli, et al.
Published: (2025-07-01)

Combination of multiple myeloma and chronic idiopathic myelofibrosis: a case report
by: N. A. Romanenko, et al.
Published: (2022-11-01)

Informative Value of Combination of Molecular Genetic and Cytogenetic Diagnostic Methods in Myelofibrosis
by: Lozynskyy R., et al.
Published: (2016-07-01)

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
by: Ruben A. Mesa, et al.
Published: (2013-06-01)

Primary myelofibrosis in rheumatic diseases
by: Vladimir Ivanovich Vasilyev, et al.
Published: (2013-04-01)

TREATMENT OF MYELOFIBROSIS: PRESENT AND FUTURE
by: Birsen Sahip Yesiralioğlu
Published: (2024-12-01)

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo
by: Weiran Li, MD, et al.
Published: (2025-10-01)

Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease: A giant leap -To start with baby steps
by: Suvir Singh
Published: (2020-01-01)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
by: Coen J. Lap, et al.
Published: (2021-01-01)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
by: Mélanie Hinterlang, et al.
Published: (2022-01-01)

Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation
by: Nurşah Eker, et al.
Published: (2022-06-01)

Special evolution in myelofibrosis – case reports
by: Iuliana Iordan, et al.
Published: (2022-01-01)

Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
by: Fuping Wang, et al.
Published: (2024-12-01)

Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis
by: Shu-yi Guo, et al.
Published: (2025-12-01)

Case Report: Successful treatment of steroid- and ruxolitinib-refractory gastrointestinal acute graft-versus-Host disease with anti-thymocyte globulin
by: Lulu Zhang, et al.
Published: (2025-07-01)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
by: Gabriel Tremblay, et al.
Published: (2021-02-01)